课题基金 / 基金详情

Isoform selective PI3 kinase inhibitors for cancer, thrombosis and inflammatory disease

Isoform selective PI3 kinase inhibitors for cancer, thrombosis and inflammatory disease
用于癌症、血栓形成和炎症性疾病的异构体选择性 PI3 激酶抑制剂
批准号:
nhmrc : 1093062
负责人:
Prof Philip Thompson
金额:
$31.64万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Development Grants
财政年份:
2015
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2015-01-01 至 2016-12-31

项目摘要

项目成果

Prof Philip Thompson的其他基金

相似基金

相关文献

中文摘要
翻译
酶的PI3激酶家族的抑制剂具有作为疾病如癌症、血栓形成和炎性疾病的治疗剂的潜力。在该项目中,研究人员将开发他们发现的一类新的PI3激酶抑制剂,优化其药物特性并在疾病模型中对其进行评估。其目的是为人类临床研究开发一种候选药物。
英文摘要
Inhibitors of the PI3 kinase family of enzymes have potential as therapeutics in diseases such as cancer, thrombosis and inflammatory disease. In this project the investigators will develop a new class of PI3 kinase inhibitors they have discovered, optimizing their pharmaceutical properties and evaluating them in models of disease. The aim is to develop a candidate for human clinical studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Anti-Infective Agents that Act by Enhancing the Host Innate Response
  • 批准号:
    nhmrc : 1099428
  • 项目类别:
    Project Grants
  • 资助金额:
    $44.93万
  • 财政年份:
    2016
  • 负责人:
    Prof Philip Thompson
  • 依托单位:
Novel Anti-Infective Agents that Act by Enhancing the Host Innate Response
  • 批准号:
    nhmrc : GNT1099428
  • 项目类别:
    Project Grants
  • 资助金额:
    $65.55万
  • 财政年份:
    2016
  • 负责人:
    Prof Philip Thompson
  • 依托单位:
Studies of the pi3-kinase enzyme family using selective inhibitors
  • 批准号:
    LP0347992
  • 项目类别:
    Linkage Projects
  • 资助金额:
    $6.49万
  • 财政年份:
    2003
  • 负责人:
    Prof Philip Thompson
  • 依托单位:
国内基金
海外基金
新型M4受体选择性拮抗剂的研究